Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Cancer Treatment Reviews

• Publication date

  1998-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0305-7372(98)90056-1PMID 9861196
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines.

  1998cited by this paper
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

  1998cited by this paper
• p53 tumor‐suppressor gene: Clues to molecular carcinogenesis

  1997cited by this paper
• A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

  1997cited by this paper
• Demonstration of a polymorphism in the gene ERCC1 by two DNA sequencing methods.

  1997cited by this paper
• Second pathway for completion of human DNA base excision‐repair: reconstitution with purified proteins and requirement for DNase IV (FEN1)

  1997cited by this paper
• Loss of heterozygosity in human ovarian cancer on chromosome 19q.

  1997cited by this paper
• A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

  1996cited by this paper
• Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.

  1996cited by this paper
• Reaction Mechanism of Human DNA Repair Excision Nuclease (*)

  1996cited by this paper
• Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

  1996cited by this paper
• Loss of DNA mismatch repair in acquired resistance to cisplatin.

  1996cited by this paper
• Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification.

  1996cited by this paper
• Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line*

  1996cited by this paper
• Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

  1996cited by this paper
• Glutathione and drug resistance.

  1996cited by this paper
• Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non‐neoplastic brain

  1996cited by this paper
• A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.

  1996cited by this paper
• Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene.

  1996cited by this paper
• A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.

  1996cited by this paper
• Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas

  1995cited by this paper
• Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.

  1995cited by this paper
• Partial characterization of the DNA repair protein complex, containing the ERCC1, ERCC4, ERCC11 and XPF correcting activities.

  1995cited by this paper
• Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes.

  1995cited by this paper
• Reconstitution of Human DNA Repair Excision Nuclease in a Highly Defined System (*)

  1995cited by this paper
• A Preliminary Risk-Benefit Assessment of Paclitaxel

  1995cited by this paper
• GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells.

  1995cited by this paper
• Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells.

  1995cited by this paper
• The base excision repair pathway.

  1995cited by this paper
• Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance.

  1995cited by this paper
• Appropriate partners make good matches.

  1995cited by this paper
• Re: M. D. Dabholkar et al., Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res., 55: 1261-1266, 1995.

  1995cited by this paper
• P53, cell cycle control and apoptosis: Implications for cancer

  1995cited by this paper
• Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.

  1995cited by this paper
• Specific association between the human DNA repair proteins XPA and ERCC1.

  1994cited by this paper
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

  1994cited by this paper
• Mismatch repair, genetic stability, and cancer.

  1994cited by this paper
• Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins.

  1994cited by this paper
• Where transcription meets repair.

  1994cited by this paper
• Platinum‐DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme‐linked immunosorbent assay

  1994cited by this paper
• Mechanisms of DNA excision repair.

  1994cited by this paper
• Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy.

  1993cited by this paper
• Expression of excision repair genes in non-malignant bone marrow from cancer patients.

  1993cited by this paper
• Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.

  1993cited by this paper
• Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

  1993cited by this paper
• Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning

  1993cited by this paper
• Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.

  1993cited by this paper
• Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

  1993cited by this paper
• Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines.

  1992cited by this paper
• Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines

  1992cited by this paper
• Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.

  1992cited by this paper
• Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy.

  1992cited by this paper
• ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

  1992cited by this paper
• Proliferating cell nuclear antigen is required for DNA excision repair.

  1992cited by this paper
• ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes.

  1992cited by this paper
• Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.

  1992cited by this paper
• High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

  1992cited by this paper
• Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

  1991cited by this paper
• Sequences of taxol and cisplatin: a phase I and pharmacologic study.

  1991cited by this paper
• Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells.

  1991cited by this paper
• Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

  1991cited by this paper
• Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.

  1991cited by this paper
• A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome.

  1990cited by this paper
• Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.

  1990cited by this paper
• Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.

  1990cited by this paper
• Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.

  1990cited by this paper
• Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.

  1990cited by this paper
• DNA repair enzymes.

  1988cited by this paper
• Mechanisms of Resistance to Platinum Drugs

  1988cited by this paper
• The measurement of cisplatin-DNA adduct levels in testicular cancer patients.

  1988cited by this paper
• In Vivo Cis-Diamminedichloroplatinum(II)-DNA Adduct Formation and Removal as Measured with Immunochemical Techniques

  1988cited by this paper
• Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides.

  1988cited by this paper
• Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay?

  1987cited by this paper
• Genomic characterization of the human DNA excision repair gene ERCC-1.

  1987cited by this paper
• cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).

  1987cited by this paper
• Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

  1987cited by this paper
• Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10.

  1986cited by this paper
• Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.

  1986cited by this paper
• Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.

  1984cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

  1982cited by this paper
• DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity.

  1979cited by this paper
• Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

  1972cited by this paper

• Distal-less homeobox 5 transactivated by MYCN contributes to progression of neuroblastoma through AKT signaling pathway.

  2025cites this paper
• Excision Repair Cross Complementation Group 1 gene exon 3 skipping isoform presents selective cGAS-STING activation in Platinum-sensitive lung adenocarcinoma.

  2025cites this paper
• Evaluation of Decreased Kidney Function in Dogs Receiving Carboplatin: A Retrospective Cohort Study of 98 Dogs (2006–2024)

  2025cites this paper
• Inhibition of DNA polymerase eta‐mediated translesion DNA synthesis with small molecule sensitises ovarian cancer stem‐like cells to chemotherapy

  2025cites this paper
• Association of ERCC1 Gene Polymorphisms (rs3212986 and rs11615) With the Risk of Lung Cancer in a Population From Southeast Iran

  2024cites this paper
• Repair of genomic interstrand crosslinks.

  2024cites this paper
• Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties

  2024cites this paper
• Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells

  2024cites this paper
• Cisplatin-induced DNA crosslinks trigger neurotoxicity in C. elegans.

  2023cites this paper
• The alternation of halobenzoquinone disinfection byproduct on toxicogenomics of DNA damage and repair in uroepithelial cells.

  2023cites this paper
• Chemosensitivity of three patient-derived primary cultures of canine pericardial mesothelioma by single-agent and combination treatment

  2023cites this paper
• Cellular landscaping of cisplatin resistance in cervical cancer.

  2022cites this paper
• INVESTIGATION OF THE EFFECT OF B-108 CONTAINING AZOMETHIN GROUP ON DNA REPAIR GENE

  2022cites this paper
• Importance of Metal Biotransformation in Cell Response to Metallic Nanoparticles: A Transcriptomic Meta-analysis Study

  2022cites this paper
• Retinal toxicities of Systemic Anticancer Drugs.

  2021cites this paper
• ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

  2021cites this paper
• Evaluation of Chemotherapeutic Drugs for Treatment of (Cisplatin-Resistant) Germ Cell Cancer Cell Lines.

  2021cites this paper
• Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer

  2021cites this paper
• ceRNA Networks: The Backbone Role in Neoadjuvant Chemoradiotherapy Resistance/Sensitivity of Locally Advanced Rectal Cancer

  2021cites this paper
• XPC Protein Improves Lung Adenocarcinoma Prognosis by Inhibiting Lung Cancer Cell Stemness

  2021cites this paper
• Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies.

  2021cites this paper
• Precision Oncology, Signaling and Anticancer Agents in Cancer Therapeutics.

  2021cites this paper
• New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors

  2021cites this paper
• Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma

  2020cites this paper
• Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.

  2020cites this paper
• Role of common ERCC1 polymorphisms in cisplatin‐resistant epithelial ovarian cancer patients: A study in Chinese cohort

  2020cites this paper
• Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer

  2020cites this paper
• ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis

  2020cites this paper
• Retraction Retracted: Apoptosis and Molecular Targeting Therapy in Cancer

  2020influential citation
• Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer

  2020cites this paper
• Irinotecan or Oxaliplatin: Which is the First Move for the Mate?

  2020cites this paper
• The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk

  2020cites this paper
• Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors

  2020cites this paper
• Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer

  2020influential citation
• A review of nutrition and dietary interventions in oncology

  2020cites this paper
• Preliminary ab initio Calculations on Pt (3D,1S) – O2 Interaction

  2020cites this paper
• New Perspectives on Unscheduled DNA Synthesis: Functional Assay for Global Genomic DNA Nucleotide Excision Repair.

  2020cites this paper
• Meta-analysis of excision repair cross complementary gene 1 (ERCC1) expression and platinum chemosensitivity in patients with ovarian cancer.

  2020cites this paper
• RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.

  2020cites this paper
• The prognostic value of excission repair cross-complementation group one enzyme expression in locally advanced cervical carcinoma patients treated with cisplatin–based treatment: a meta–analysis

  2019cites this paper
• Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy

  2019cites this paper
• Effect of the Interaction Between Selenium and Zinc on DNA Repair in Association With Cancer Prevention

  2019cites this paper
• Molekularbiologische Aspekte bei der Entstehung und Behandlung von Keimzelltumoren

  2019cites this paper
• Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

  2019cites this paper
• Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer

  2019cites this paper
• Cytoprotective effects of sinapic acid on human keratinocytes (HaCaT) against ultraviolet B

  2018cites this paper
• Correlation analysis between polymorphism of GSTP1, XPD and XRCC1 gene in esophageal carcinoma patients and treatment efficiency of cisplatin chemo-therapy

  2018cites this paper
• Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma

  2018cites this paper
• Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer.

  2018cites this paper
• Genetic variants in nucleotide excision repair pathway predict survival of esophageal squamous cell cancer patients receiving platinum‐based chemotherapy

  2018cites this paper
• Research on correlations of ERCC-1 with proliferation and apoptosis of ovarian cancer cells.

  2018cites this paper
• Profiles of brain metastases: Prioritization of therapeutic targets

  2018cites this paper
• Επίδραση κυτταροτοξικών δράσεων συμπλόκων του βαναδίου στην ανάπτυξη κυτταρικών σειρών σαρκωμάτων

  2018cites this paper
• Anticancer platinum‐based complexes with non‐classical structures

  2018cites this paper
• Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy

  2018cites this paper
• LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions.

  2018cites this paper
• Platinum derivatives: a multidisciplinary approach.

  2017cites this paper
• Biological and predictive role of ERCC1 polymorphisms in cancer.

  2017cites this paper
• ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy

  2017cites this paper
• RHAMM-target peptides inhibit invasion of breast cancer cells

  2017cites this paper
• Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis

  2017cites this paper
• Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy

  2017cites this paper
• Identification of Genes under Purifying Selection in Human Cancers

  2017cites this paper
• Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy

  2017cites this paper
• Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

  2017cites this paper
• Introduction Platinum derivatives : a multidisciplinary approach

  2017cites this paper
• MiRNA-124-3p Reduces Cell Viability in Cisplatin Resistant Neuroblastoma Cell Models.

  2017cites this paper
• Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

  2016cites this paper
• Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

  2016cites this paper
• Base-Resolution Analysis of Cisplatin-DNA Adducts at the Genome Scale.

  2016cites this paper
• Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin

  2016cites this paper
• Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells

  2016influential citation
• Prognostic role of excision repair cross complementing-1 and topoisomerase-1 expression in epithelial ovarian cancer.

  2016cites this paper
• Chemoresistance and targeted therapies in ovarian and endometrial cancers

  2016influential citation
• Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

  2016influential citation
• ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis

  2016cites this paper
• Flap endonuclease 1 silencing is associated with increasing the cisplatin sensitivity of SGC‑7901 gastric cancer cells.

  2016cites this paper
• Role of Pkc Delta in Uv Radiation Dna Damage Repair

  2016cites this paper
• The non-Wnt functions of APC : unravelling the link between APC and apoptosis

  2016cites this paper
• A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy

  2016cites this paper
• Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.

  2016cites this paper
• Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags

  2016cites this paper
• Lovastatin prevents cisplatin-induced activation of pro-apoptotic DNA damage response (DDR) of renal tubular epithelial cells.

  2016cites this paper
• Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.

  2016cites this paper
• DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1

  2016cites this paper
• Capecitabine for treating head and neck cancer

  2016cites this paper
• Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).

  2016cites this paper
• Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients.

  2016cites this paper
• Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer.

  2015cites this paper
• Investigation of some DNA repair genes association in non small cell lung cancer.

  2015cites this paper
• Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells

  2015cites this paper
• Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer

  2015cites this paper
• Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer

  2015cites this paper
• Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.

  2015cites this paper
• Functional characterization of the nitrogen permease regulator-like-2 candidate tumor suppressor gene in colorectal cancer cell lines

  2015cites this paper
• Biomarkers of head and neck cancer, tools or a gordian knot?

  2015cites this paper
• ResearchUp-regulation of fas reverses cisplatin resistance of human small cell lung cancer cells

  2015cites this paper
• Confluence analysis of multiple omics on platinum resistance of ovarian cancer.

  2015cites this paper
• Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer.

  2015cites this paper
• Association between ERCC 1 and XPF polymorphisms and risk of colorectal cancer

  2015cites this paper